Rexahn Begins Patient Enrolment for Depressive Disorder Study

Rexahn's patient enrolment will be conducted through the first half of this year for the treatment study for depressive disorder.

Rexahn Pharmaceuticals has initiated patient enrolment for a Phase IIb clinical trial evaluating Serdaxin as treatment for major depressive disorder (MDD).

The randomised, double blind and placebo-controlled study will enrol up to 300 patients, and will be conducted at 40 sites across the US. Patient enrolment will be conducted through the first half of 2011, with preliminary data expected later in the year.

Serdaxin will be administered as an oral, extended release tablet.

Rexahn president Rick Soni said that data from Phase IIa study for major depressive disorder suggested that Serdaxin has the potential to improve symptoms of the condition without the side effects commonly associated with current antidepressant